ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Regulus cuts jobs after oligonucleotide safety setback

by Michael McCoy
July 13, 2018 | APPEARED IN VOLUME 96, ISSUE 29

 

Regulus Therapeutics, a biotech firm developing oligonucleotide drugs that target microRNAs, will cut 60% of its workforce, or about 35 jobs. The decision follows the observation of acute mouse toxicity in a Phase I study of RGLS4326, a treatment for autosomal dominant polycystic kidney disease. The firm also halted recruitment for a study of a microRNA drug it is developing with Sanofi.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment